Boston University
Targeted use of camptothecin as a specific pharmacological agent for the treatment of triple negative breast cancer
Abstract
dc:description.abstractTriple negative breast cancer (TNBC) accounts for 15 to 20% of all new breast cancers diagnosed in the United States. This figure increases to greater than 30% in minority populations. Currently, targeted therapeutic options are not available for TNBC, thus resulting in the use of general chemotherapeutics and lower survival rates for those afflicted with the disease. Camptothecin and its structural analogues (CPTs) are specific, reversible inhibitors of topoisomerase I (topoi), and have recently shown promise in the treatment ofTNBC, with a response rate of nearly 40%. CPTs are targeted drugs, but only effective within a subset of cancer patient populations. In order to understand the regulation of topoi upon CPT administration and elucidate the resistance mechanism, we isolated a topoi interacting protein complex. We further investigated the role of proteins associated with topoi, and have determined that: (I) following CPT administration, topoi is phosphorylated at serine 10 (S10) by the DNA-PK/Ku-70/Ku-80 complex, (II) S10 phosphorylation ensures the ubiquitination oftopoi by the BRCA1/BARD1 heterodimer, (Ill) topoi is subsequently degraded by the ubiquitin-proteasomal pathway (UPP), and (IV) the rate oftopoi degradation determines the cellular response to CPT. In summary, BRCA1/BARD1 E3 ligase activity leads to the ubiquitination and rapid degradation of to poi, conferring cellular resistance to CPT. Phosphorylation levels of S10 on topol correlates to the rate of topol degradation, thus can be used as a predictive biomarker for CPT response. Taken together, CPT can be an effective treatment for a subset of the TNBC patient population.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Molecular Medicine
- Grantor dc:publisher
- Boston University
- Year dc:date.issued
- 2013
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Shah, Ankur K.
Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Dc Identifier Other
- (ALMA)contemp